Skip to main content
OpenTrials
Terminated

NCT Number: NCT03377517

Radiosurgical Hypophysectomy for Bone Metasteses Pain

This research is being done to see if a delivery of a single high dose of radiation therapy to a small area of the pituitary gland and pituitary stalk in a highly precise manner may be helpful in reducing intractable pain from bone metastases.

Why the study stopped: Accrual was slower than anticipated and funding was not extended beyond original contract.
Terminated

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The Sidney Kimmel Comprehsensive Cancer Center at Johns Hopkins

Baltimore, Maryland, 21287, United States

About this study

Although not currently standard of care, small series suggest both safety and efficacy of radiosurgical hypophysectomy in reducing cancer pain from bone metastases. In spite of the demonstrated feasibility in meeting normal tissue constraints and preliminary data suggestive of both safety and efficacy, radiosurgical hypophysectomy is rarely performed in clinical practice, and many radiation oncologists are not even aware of its potential to reduce intractable cancer pain. This is likely because, to date, well-designed prospective studies have not been performed to further explore both the safety and efficacy of the intervention. This single arm pilot study is designed to fill that void. If successful, the investigators plan to utilize the data to support the proposal of a larger scale follow-up clinical trial.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Cytologic proof of malignancy
  • Radiographic evidence of bone metastases
  • Intractable pain uncontrolled by opioids, medical management, injections/ablation or surgical intervention that would be difficult to address with conventional radiation therapy or other standard options and is limiting the patient's function and quality of life. Intractable pain will be defined as a visual analogue score of at least 4.
  • Definitive radiographic progression of osseous and/or visceral metastases on standard staging scans (CT, MRI, bone scan, PET scan or any other standard of care imaging) performed within the last 3 months in spite of standard oncologic interventions and/or inability to tolerate standard oncologic interventions
  • Life expectancy at least 4 weeks
  • Age≥ 18 years
  • Patients of childbearing potential (male or female) must practice adequate contraception due to possible harmful effects of radiation therapy on an unborn child
  • Patient must have the ability to understand and the willingness to sign a written informed consent document
  • All patients must be informed of the investigational nature of this study and must be given written informed consent in accordance with institutional and federal guidelines

Exclusion criteria

  • Prior brain radiation
  • Patients must not have a serious medical or psychiatric illness that would, in the opinion of the treating physician prevent informed consent or completion of protocol treatment
  • Isolated localized pain amenable to focal radiation therapy, or pain well controlled by opioids, medical management, injections/ablation or surgical intervention
  • Malignancies being managed with curative intent
  • Life expectancy <4 weeks
  • The tumor amenable to curative management

Treatment and study plan

radiosurgical hypophysectomy

Radiation

Patients will be treated to a dose of 150 Gy in a single fraction. All patients will undergo CT simulation with 1 mm slices as well as MRI simulation including at least high resolution 1 mm slice T1 weighted MRI. They will be treated in a supine position using an aquaplast mask system for immobilization.

Primary outcomes

  1. Change in Intensity of Bone Pain

    Time frame: Post treatment day 10

    To estimate the rate of clinically meaningful decrease in diffuse osseous pain following radiosurgical hypophysectomy at 4 weeks following completion of radiosurgical hypophysectomy. Score range 0-10, higher score worse pain. A 2 point reduction in the worst pain severity score on the Brief Pain Index (ie: question number 3) at 4 weeks following completion of radiosurgical hypophysectomy compared to baseline will be considered as clinically meaningful decrease.

Secondary outcomes

  1. Participants With Reduction in Opioid Utilization Following Radiosurgical Hypophysectomy

    Time frame: Approximately 28 weeks following completion of radiosurgical hypophysectomy

    To estimate the rate of reduction in opioid utilization following radiosurgical hypophysectomy

  2. Participants With Radiation Induced Optic Neuropathy Following Radiosurgical Hypophysectomy

    Time frame: Approximately 28 weeks following completion of radiosurgical hypophysectomy

    To estimate the risk of radiation induced optic neuropathy following radiosurgical hypophysectomy

  3. Participants With Radiation-associated Acute and Long Term Neurologic Toxicity

    Time frame: Approximately 28 weeks following completion of radiosurgical hypophysectomy

    To estimate the radiation-associated acute and long term neurologic toxicity of radiosurgical hypophysectomy

Interested in participating?

Terminated

Looking for future studies?

Notify Me

Sponsors and collaborators

Lead sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Other

Collaborators

  • Accuray Incorporated

Registry information

Official study title

A Pilot Study of Stereotactic Radiosurgical Hypophysectomy for Intractable Pain From Bone Metastases

Important dates

Study start
2018
Primary completion
2024
Study completion
2024
First posted
Dec 19, 2017
Registry last updated
Sep 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.